Register Now for Access! 2024
AAM’s annual meeting Access! 2024 brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Discussions center around the business, breakthroughs and politics that shape our industry. It’s the opportunity to hear firsthand from world-renowned speakers and learn about where our industry is heading and what our future holds. Register now!
2023 U.S. Generic and Biosimilar Medicines Savings Report
New findings in the 2023 U.S. Generic & Biosimilar Medicines Savings Report show savings for generics and biosimilars continue to grow with $408 billion saved in 2022 for patients, consumers, employers and taxpayers. Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are an integral part of the U.S. health care system. Read full report.
The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.
Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market
Biosimilars approved in the U.S.
Billion in potential savings for patients and payers
Million days of patient therapy where biosimilars were used
Million additional days of patient therapy
The Benefits of Biosimilars
Recent Blogs & Resources
What Patients Are Saying
Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”
Helen, 41, Florida
Listen to their stories.
You Can Make A Difference
As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.